Retired Health Care Executive. ISPOR President 2023-24. Veteran. Colonel Commandant of the Royal Cdn Medical Svc. Former President & CEO of CADTH. Bruins fan.
Very pleased to be representing @ISPORorg at the @ICHOM2023 conference in Barcelona. 650 delegates from 46 countries attending the conference to share and learn about the important work being done by @ICHOM_ORG in developing core outcome sets.
@Care4Access provides clear rationale to support why patients prefer non-randomised clinical trials in oncology, particularly for rare cancers. #ISPOREurope session on the pros and cons of single arm trials in oncology.
Second plenary at #ISPOREurope is focused on real world use of patient-centred research, with a description of the Darwin EU initiative from the @EMA_News Many questions arise with Darwin, including whether it will be used to support both regulatory and reimbursement decisions.
Thank you to all of the participants of the 2022 ISPOR Health Technology Assessment Roundtable - Europe for an engaging and fruitful dialogue! Special thanks to the Chairs for their exceptional leadership and the speakers for their insightful presentations. #ISPOREurope#HTA
It’s the 71st annual CMHA Mental Health Week!
Please read this important message from the CAF Surgeon General: https://t.co/VRgz896bgT
Also, keep your eyes on the @CFHSvcs account for content throughout the week.
#CMHW2022#GetReal#MentalHealth#WellBeing
Announcing the release of the INAHTA Position Statement on Disruptive Technologies! This statement reflects members’ views on the concept of disruptive technologies – a topic of significant interest amongst the INAHTA membership. View full statement here: https://t.co/XSZwvGkqnf
Hey, fellow @ISPORorg members! It’s time to vote for your next president! Here’s a little video message from me about this election & videos from each of our two brilliant candidates: @jasminepwu and @ORourke_B
⬇️
https://t.co/awgy4nyxF4
The ballot is now open, so VOTE!!🗳️
Plenary 1: Rui Santos Ivo of @INFARMED_IP discusses an integrated approach and areas of action in scientific and regulatory advice including promoting timely access to medicines that introduce added value at a fair price, sustainable to NHS. #ISPOREurope#HTA
During the opening plenary at #ISPOREurope Dr. Hans-Georg Eichler stated that drugs with a small effect size and a small target population will have unavoidable uncertainty and that conventional HTA approaches will not be feasible. @ISPORorg
Opening plenary at #ISPOREurope Dr. Jo De Cock from INAMI Belgium describing a multi-stakeholder, international payer led initiative called RWE4Decisions. A key point mentioned by Dr. De Cock is that Outcomes-based MEAs should contain a clear RWE generation plan. @ISPORorg
ISPOR is thinking about many things, states @NbergBerg, including: Effectively communicating the value of #HEOR. Supporting #payers & decision makers. Digital transformation of #healthcare. Aligning HEOR and #technology. And more! #ISPOREurope
@kidd_beth sharing issues of importance to patients throughout the pandemic. Equity, trust, eldercare, maintaining momentum on virtual care, and streamlined access to necessary treatments were all highlighted. #CADTHsymp
@NeilD_Fraser highlights three key issues to address coming out of the pandemic - supply chains, high levels of debt, and health Human Resources. #CADTHSymp
INAHTA and @HTAiOrg have renewed their Memoranda of Understanding, continuing a long & valuable relationship. The MOU, originally signed in 2008, was renewed in 2021 ensuring that MOU activities are ready for the future of HTA. Thank you HTAi, for being a great MOU partner!